Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2013 2
2014 2
2015 1
2016 8
2017 12
2018 8
2019 11
2020 21
2021 20
2022 15
2023 22
2024 21
2025 23
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean minqin xu (4 results)?
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study.
Huang Z, Karaboué A, Zeng L, Lecoeuvre A, Zhang L, Li XM, Qin H, Danino G, Yang F, Malin MS, Deng L, Rigal M, Liu H, Chen X, Xu Q, Grimaldi L, Collon T, Wang J, Adam R, Yang N, Duchemann B, Zhang Y, Lévi F. Huang Z, et al. Among authors: xu q. EBioMedicine. 2025 Mar;113:105607. doi: 10.1016/j.ebiom.2025.105607. Epub 2025 Feb 20. EBioMedicine. 2025. PMID: 39983330 Free PMC article.
Third left pulmonary lobe.
Zeng L, Xu Q, Yang N, Lizaso A, Zhang Y. Zeng L, et al. Among authors: xu q. Thorax. 2021 May;76(5):525. doi: 10.1136/thoraxjnl-2020-216130. Epub 2020 Nov 23. Thorax. 2021. PMID: 33229403 No abstract available.
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
Zeng L, Ruan Z, Yan H, Qin H, Zeng Z, Zou C, Huang Z, Jiang W, Dai J, Xu S, Song L, Chen Y, Zhang Y, Zeng F, Wei S, Chen S, Liu L, Xiong Y, Wang Z, Deng J, Zhang X, Sun Y, Yang D, Zhou C, Yang H, Li Y, Deng L, Xu Q, Fang C, Chen X, Wang J, Li T, Zhang G, Zhou H, Yang N, Zhang Y. Zeng L, et al. Among authors: xu q. Nat Commun. 2025 Dec 15;17(1):567. doi: 10.1038/s41467-025-67262-x. Nat Commun. 2025. PMID: 41398162 Free PMC article. Clinical Trial.
Simultaneous deep transcriptome and proteome profiling in a single mouse oocyte.
Jiang YR, Zhu L, Cao LR, Wu Q, Chen JB, Wang Y, Wu J, Zhang TY, Wang ZL, Guan ZY, Xu QQ, Fan QX, Shi SW, Wang HF, Pan JZ, Fu XD, Wang Y, Fang Q. Jiang YR, et al. Cell Rep. 2025 Jun 24;44(6):115932. doi: 10.1016/j.celrep.2025.115932. Epub 2025 Jun 13. Cell Rep. 2025. PMID: 40516051 Free article. No abstract available.
Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC.
Song L, Zeng L, Xu Q, Li Y, Guo W, Lin S, Jiang W, Wang Z, Deng L, Huang Z, Qin H, Yan H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Yu J, Yang X, Xia Y, Dong X, Zhang G, Yang N, Zhang Y. Song L, et al. Among authors: xu q. iScience. 2025 Jul 25;28(9):113211. doi: 10.1016/j.isci.2025.113211. eCollection 2025 Sep 19. iScience. 2025. PMID: 40831747 Free PMC article.
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial.
Zeng L, Yan H, Jiang W, Qin H, Dai J, Zhang Y, Wei S, Chen S, Liu L, Xiong Y, Yang H, Li Y, Wang Z, Deng L, Xu Q, Peng L, Zhang R, Fang C, Chen X, Deng J, Wang J, Li T, Liu H, Zhang G, Yang N, Zhang Y. Zeng L, et al. Among authors: xu q. Med. 2025 Jun 13;6(6):100574. doi: 10.1016/j.medj.2025.100574. Epub 2025 Jan 31. Med. 2025. PMID: 39892382 Clinical Trial.
155 results